Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target

Immunome (IMNM) has received a new Buy rating, initiated by H.C. Wainwright analyst, Andres Y. Maldonado.

Andres Y. Maldonado has given his Buy rating due to a combination of factors tied to Immunome’s differentiated oncology portfolio and execution potential. He highlights varegacestat as a leading gamma-secretase inhibitor in desmoid tumors, citing stronger tumor shrinkage, progression-free outcomes, and response rates versus the current approved option, along with an efficacy and safety balance that could support blockbuster-level sales within the next decade.

He also emphasizes Immunome’s emerging ADC platform, led by IM-1021 and powered by a high-throughput discovery engine that marries overlooked targets with refined linker–payload chemistry, including a proprietary TOP1 inhibitor designed to counter chemoresistance. Combined with a pipeline of additional ADC candidates, a FAP-targeted radioligand program, and a management team with a proven history of commercializing major oncology drugs, he views Immunome as positioned for both near-term catalysts and sustained, multi-asset growth, justifying the Buy rating and $40 price target.

In another report released on February 4, TipRanks – Google also upgraded the stock to a Buy with a $30.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMNM in relation to earlier this year.